The Pharma Data

DECEMBER 1, 2020

NEW YORK & MAINZ, Germany–( BUSINESS WIRE )– Pfizer Inc. Pfizer and BioNTech are anticipating further regulatory decisions across the globe in the coming days and weeks and are ready to deliver vaccine doses following potential regulatory authorizations or approvals. 2, 2020 07:05 UTC.

Vaccination 40

Vaccination Vaccine Manufacturing Clinical Trials 40

Pfizer

DECEMBER 20, 2022

FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. Pfizer oral treatment remains available to eligible U.S. Pfizer oral treatment remains available to eligible U.S. NEW YORK, December 20, 2022 -- Pfizer Inc.

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

FEBRUARY 25, 2021

FDA ACCEPTS FOR PRIORITY REVIEW PFIZER’S APPLICATION FOR TICOVAC (TICK-BORNE ENCEPHALITIS VACCINE). NEW YORK–(BUSINESS WIRE)– Pfizer Inc. Global President, Vaccines, Pfizer Inc. “If More than 40 years of experience with the Pfizer TBE vaccine exist outside the U.S., We are proud that today’s U.S.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 2, 2022

Myovant Sciences (NYSE: MYOV) and Pfizer Inc. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 of women who discontinued treatment and initiated placebo at Week 52 (p < 0.0001).

Drugs 52

Drugs Hormones Development Medicine 52

The Pharma Data

MARCH 3, 2021

Food and Drug Administration (FDA) approved Pfizer Inc.’s s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). About the CROWN Trial.

FDA Approval 52

FDA Approval Hormones Trials Medicine 52

Pfizer

OCTOBER 28, 2022

New York, October 28, 2022 — Pfizer Inc. 1,2,3 As the developer of tofacitinib, Pfizer is committed to advancing the science of Janus kinase inhibition and enhancing understanding of tofacitinib through robust clinical development programs in the treatment of immune-mediated inflammatory conditions. Pfizer Inc.:

Clinical Trials 40

Clinical Trials Clinical Trials Vaccination Vaccine 40

The Pharma Data

JUNE 16, 2021

NEW YORK–(BUSINESS WIRE)– Pfizer Inc. The trial was a research collaboration between Pfizer and the ARO from the Hospital Israelita Albert Einstein in Sao Paulo, Brazil, which was the trial coordinating center. to 0.97; p=0.04). Chief Medical Officer, Pfizer Inflammation & Immunology. “As

Medicine 40

Medicine Clinical Trials Clinical Trials Trials 40

pharmaphorum

JUNE 9, 2022

For instance, earlier last month Pfizer and Sidekick Health launched a new dermatitis app aimed at improving medication management of patients with skin diseases and Akili partnered with Robolox expanding children’s access to EndeavorRx, a novel ADHD digital therapy. Table 1: P&R assessment criteria Germany, UK, France, and the USA.

Marketing 144

Marketing Manufacturing Production Regulation 144

Pfizer

DECEMBER 8, 2022

Pfizer and BioNTech Receive U.S. Pfizer and BioNTech Receive U.S. NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. INDICATION & AUTHORIZED USE Pfizer-BioNTech COVID-19 Vaccine, Bivalent, (Original and Omicron BA.4/BA.5) Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. NEW YORK and MAINZ, GERMANY, November 3, 2022 — Pfizer Inc. AUTHORIZED USE.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

AUGUST 22, 2021

We are proud to make these new options available in the EU as Pfizer continues to advance the science and understanding of medicines like XELJANZ, which has been studied in more than 50 trials across clinical programs worldwide.”. Pfizer is also continuing to work with the U.S.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

The Pharma Data

SEPTEMBER 10, 2021

Myovant Sciences (NYSE: MYOV) and Pfizer Inc. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 Myovant and Pfizer are jointly developing and commercializing MYFEMBREE in the U.S. In the U.S.,

Hormones 52

Hormones FDA Approval Drugs Development 52

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. Pfizer and BioNTech’s COVID-19 Vaccine. billion in June. ECONOMIC IMPACT: Canada.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92